Business
Halberd Corporation's Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens
Halberd Corporation's Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens.
About this update from Halberd Corp.
[{"type":"text","content":"Paves Way for Disease Elimination by Radio Frequency WavesJACKSON CENTER, PA / ACCESSWIRE / March 30, 2021 / Halberd Corporation (OTC PINK:HALB) has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody's antigen-neutralizing properties. This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through the use of radio frequency (RF) energy.The moieties (nanoparticles conjugated with an antibody and antigen) resonate (vibrate) at their natural frequency when exposed to a tuned radio frequency. This causes heating of the conjugate and destroys the disease antigen, thus eliminating "the pathophysiologic basis of the disease."Halberd has also successfully conjugated metallic nanoparticles with E. Coli antibodies, demonstrating the technology can be used against other disease antigens.William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "We are moving quickly to protect the intellectual property present in Halberd's creation of these metallic moieties (conjugated nanoparticle-antibody-antigen), but cannot reveal any specifics of the technology at this time. We believe this is a huge step towards our ultimate goal of being able to target a wide range of disease antigens for elimination through the use of radio frequency signals in our patented extracorporeal setting! We are also moving quickly to commence laboratory testing of the effectiveness of RF in eliminating the target antigens with two of our university partners over the next several weeks."To get the latest news on Halberd's exciting developments, subscribe by submitting this form.(https://halberdcorporation.com/contact-us/)For more information please contact:William A. [email protected]@halberdcorporation.comwww.halberdcorporation.comTwitter:@HalberdCAbout Halberd Corporation.Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to several patent pending COVID-19 extracorporeal treatments:The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional pate...